Glutamatergic neurotransmission in schizophrenics;Glutamaterge neurotransmission bei schizophrenien

Fortschritte der Neurologie Psychiatrie

Volumn 69, Issue SUPPL. 2, 2001, Pages

  Bleich, S ^a   Bleich, K ^a   Wiltfang, J ^a   Maler, J M ^a   Kornhuber, J ^b  

^a UNIVERSITY OF GÖTTINGEN   (Germany)

^b UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTAMATE RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR STIMULATING AGENT;

CONFERENCE PAPER; DRUG EFFICACY; EXCITATORY JUNCTION POTENTIAL; HUMAN; INFORMATION PROCESSING; NEOCORTEX; NEUROCHEMISTRY; NEUROTRANSMISSION; PATHOPHYSIOLOGY; PROTEIN SECRETION; SCHIZOPHRENIA; THALAMUS;

GLUTAMIC ACID; HUMANS; SCHIZOPHRENIA; SYNAPTIC TRANSMISSION;

EID: 0034810393     PISSN: 07204299     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (59)

1. Plasma and platelet excitatory amino acids in psychiatric disorders
2. Increased density of glutamate/N-methyl-D-aspartate receptors in putamen from schizophrenic patients
3. A family study of schizophrenic and normal control probands: Implications for the spectrum concept of schizophrenia
4. Neurotensin and the mesocorticolimbic dopamine system
5. Oxidative stress and an altered methionine metabolism in alcoholism
6. Repeated ethanol withdrawal delays development of focal seizures in hippocampal kindling
7. Elevated homocysteine levels in alcohol withdrawal
8. The current status of the dopamine hypothesis of schizophrenia
9. Effect of chlorpromazine and haloperidol on the formation of 3-methoxytyramine and normetanophrine in mouse brain
10. Neurotransmitter aberrations in schizophrenia: New findings
11. d-cycloserine adjuvant therapy to conventional neuroleptic treatment in schizophrenia: An open-label study
12. An open trial of glycine as an adjunct to neuroleptics in chronic treatment-refractory schizophrenics
13. A re-evaluation of the viral hypothesis: Is psychosis the result of retroviral integration at a side close to the cerebral dominance gene?
14. Adenosinergic psychopharmaceuticals: Just an extra cup of coffee?
15. GluR2 glutamate receptor subunit flip and flop isoforms are decreased in the hippocampal formation in schizophrenia: A reverse transcriptase-polymerase chain reaction (RT-PCR) study
16. D2 dopamine receptors in neuroleptic-naive schizophrenic patients. A positron emission tomography study with [11C]raclopride
17. Possible association of schizophrenia with a disturbance in prostaglandin metabolism. A physiological hypothesis
18. Ionotropic glutamate receptors and expression of N-methyl-D-aspartate receptor subunits in subregions of human hippocampus: Effects of schizophrenia
19. The interaction between GABA and dopamine: Implications for schizophrenia
20. Sensorische störungen bei schizophrenien
21. Psychiatric disorders in faster home reared children of schizophrenic mothers
22. Schizophrenia as a prostaglandin deficiency disease
23. CNS signal transduction in the pathophysiology and pharmacotherapy of affective disorders and schizophrenia
24. Recent advances in the phencyclidine model of schizophrenia
25. Amelioration of negative symptoms in schizophrenia by glycine
26. Reversal of phencyclidine-induced effects by glycine and glycine transport inhibitors
27. Choline acetyltransferase in schizophrenia
28. Low cerebrospinal fluid glutamate in schizophrenic patients and a new hypothesis on schizophrenia
29. Memantin
30. Zur biochemischen theorie der schizophrenie
31. Aktueller stand der biochemischen hypothesen zur pathogenese der schizophrenien
32. Phencyclidin und das glutamaterge system
33. Psychotogenicity and NMDA receptor antagonism: Implications for neuroprotective pharmacotherapy
34. 3H-spiperone binding sites in post-mortem brains from schizophrenic patients: Relationship to neuroleptic drug treatment, abnormal movements, and positive symptoms
35. 3H]MK-801 binding sites in postmortem brain regions of schizophrenic patients
36. Modellvorstellungen zur ätiopathogenese der schizophrenien
37. Cerebrospinal fluid amino acid concentrations in chronic schizophrenia
38. Neurochemistry and neuroendocrinology of schizophrenia: A selective review
39. Excitatory amino acids as a final common pathway for neurological disorders
40. Clinical studies on the mechanism of action of clozapine: The dopamine-serotonin hypothesis of schizophrenia
41. Cholecystokinin and schizophrenia
42. Pathological changes induced in cerebrocortical neurons by phencyclidine and related drugs
43. Increased dopamine-receptor sensitivity in schizophrenia
44. Psychiatric and medical syndromes with phencyclidine (PCP) abuse
45. Beyond the dopamine hypothesis. The neurochemical pathology of schizophrenia
46. The relative abundance of dopamine D4 receptor mRNA in post mortem brains of schizophrenics and controls
47. Dopamine D4 receptors elevated in schizophrenia
48. In vitro and in vivo inhibition of N-acetyl-L-aspartyl-L-glutamate catabolism by N-acylated L-glutamate analogs
49. d-Cycloserine therapy of psychosis by symptom provocation
50. Interaction between glutamatergic and dopaminergic tone in the nucleus accumbens of mice: Evidence for a dual glutamatergic function with respect to psychomotor control
51. Cholinergic hyperactivity and negative schizophrenic symptoms. A model of cholinergic/dopaminergic interactions in schizophrenia
52. Increased CSF levels of endorphins in chronic psychoses
53. Excitatory amino acid agonists and antagonists: Pharmacology and therapeutic applications
54. Abnormal excitatory neurotransmitter metabolism in schizophrenic brains
55. Sigma receptors: Biology and function
56. Glycine therapy of schizophrenia
57. Endorphins and schizophrenia